Apimeds Pharmaceuticals US, Inc.
Close on Oct 19, 2026
- Market cap
- $6.00M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Apimeds Pharmaceuticals US has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Apimeds Pharmaceuticals US filed with the SEC
PRESS RELEASE ISSUED BY MINDWAVE INNOVATIONS INC. DATED OCTOBER 4, 2026 (BLOCKASSURE)
Other events · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED BY MINDWAVE INNOVATIONS INC. DATED SEPTEMBER 24, 2026 (AQUAECHAIN)
Other events · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED BY MINDWAVE INNOVATIONS INC. DATED SEPTEMBER 29, 2026 (FLASHCHAIN)
Other events · EX-99.2 to Form 8-K
PRESS RELEASE ISSUED BY MINDWAVE INNOVATIONS INC. DATED MARCH 24, 2026
Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED DECEMBER 1, 2025
Material agreement · Acquisition or disposition completed · New financial obligation · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE DATED JULY 15, 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED MAY 8, 2025
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED MAY 12, 2025
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K